<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003927</url>
  </required_header>
  <id_info>
    <org_study_id>99002</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-IRB-99002</secondary_id>
    <secondary_id>ALZA-CHNMC-IRB-99002</secondary_id>
    <secondary_id>NCI-G99-1527</secondary_id>
    <secondary_id>CDR0000067115</secondary_id>
    <nct_id>NCT00003927</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer</brief_title>
  <official_title>High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
      Amifostine may protect normal cells from the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, amifostine,&#xD;
      and peripheral stem cell transplantation in treating patients who have stage II, stage III,&#xD;
      or stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the feasibility of high dose doxorubicin, cyclophosphamide,&#xD;
      paclitaxel, and amifostine in patients with high risk stage II/III and responsive stage IV&#xD;
      advanced breast cancer. II. Determine the pharmacokinetic profile of paclitaxel administered&#xD;
      with amifostine in this regimen in these patients. III. Assess the toxicity of this treatment&#xD;
      regimen in this patient population.&#xD;
&#xD;
      OUTLINE: Patients receive filgrastim (G-CSF) subcutaneously twice daily on days 1-4 for&#xD;
      peripheral blood stem cell (PBSC) mobilization and continuing through days 5-10 during PBSC&#xD;
      collection. At least 2 weeks following mobilization, patients receive doxorubicin IV as a&#xD;
      continuous infusion on days -9 through -5 followed by cyclophosphamide IV over 2 hours on day&#xD;
      -5 and amifostine IV over 15 minutes, and paclitaxel IV over 24 hours on day -4. On day -2,&#xD;
      25% PBSC are reinfused and 75% are reinfused on day 0, followed by daily G-CSF subcutaneously&#xD;
      or IV beginning on day 1. Patients are followed every 3 months for 2 years, then periodically&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 6-8 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 18, 1999</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of high dose chemotherapy in advance breast cancer patients.</measure>
    <time_frame>Up to death</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>High Dose chemotherapy followed by cell rescue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin, cyclophosphamide, Taxol, amifostine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>High Dose chemotherapy followed by cell rescue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
    <arm_group_label>High Dose chemotherapy followed by cell rescue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>High Dose chemotherapy followed by cell rescue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>High Dose chemotherapy followed by cell rescue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>High Dose chemotherapy followed by cell rescue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>High Dose chemotherapy followed by cell rescue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven breast cancer including: Stage IV metastatic&#xD;
        disease with current partial or complete response to prior induction chemotherapy High risk&#xD;
        primary disease with less than 60% chance of progression free survival at 3 years Stage II&#xD;
        tumors with 10 or more axillary node involvement Stage IIIA or IIIB tumors No bone marrow&#xD;
        metastases No CNS metastases No more than 10 bone metastases Hormone receptor status: Not&#xD;
        specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 59 and under Menopausal status: Not specified Performance&#xD;
        status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Neutrophil count&#xD;
        greater than 2,000/mm3 Platelet count greater than 150,000/mm3 Hemoglobin greater than 9&#xD;
        g/dL (blood transfusions allowed) Hepatic: Bilirubin no greater than 1.2 mg/dL SGOT or SGPT&#xD;
        less than 1.5 times upper limit of normal Renal: Creatinine no greater than 1.2 mg/dL&#xD;
        Creatinine clearance at least 80 mL/min No prior hemorrhagic cystitis Cardiovascular:&#xD;
        Ejection fraction at least 55% by MUGA No prior valvular heart disease or arrhythmia&#xD;
        Pulmonary: DLCO at least 60% lower limit of predicted pCO2 no greater than 43 mmHg on room&#xD;
        air pO2 greater than 85 mmHg on room air FEV 1 at least 2 liters Other: No other prior&#xD;
        malignancy except basal or squamous cell skin cancer, or carcinoma in situ or stage I&#xD;
        carcinoma of the cervix Not pregnant HIV negative Hepatitis B negative No prior history of&#xD;
        disabling psychosocial disorder No other CNS dysfunction&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease&#xD;
        Characteristics At least 4 weeks since prior chemotherapy No more than 2 prior chemotherapy&#xD;
        regimens for metastatic disease Prior total doxorubicin dose no greater than 180 mg/m2&#xD;
        Prior total paclitaxel dose no greater than 750 mg/m2 Endocrine therapy: At least 4 weeks&#xD;
        since prior hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy No&#xD;
        prior radiotherapy to the left chest wall No prior radiotherapy to greater than 20% of bone&#xD;
        marrow (excluding syngeneic transplantation candidates) Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Somlo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center and Beckman Research Institute, City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>January 4, 2023</last_update_submitted>
  <last_update_submitted_qc>January 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

